Tag: Hodgkin Lymphoma

How can we further improve lymphoma care?

Expert
Lorna Warwick, Lymphoma Coalition

14 September 2023 09:16

First-line nivolumab-AVD improves PFS both in adult and paediatric patients with advanced Hodgkin lymphoma

Presented By
Prof. Alex Herrera, City of Hope Medical Center, CA, USA
Trial
Phase 3, SWOG S1826
Conference
ASCO 2023
Type
Peer-reviewed article

1 August 2023 12:38

Next-generation cell therapies for cancer: CAR-NK cells

Presented By
Dr Katy Rezvani, MD Anderson Cancer Center, TX, USA
Conference
EBMT 2023
Type
Peer-reviewed article

15 June 2023 17:20

Novel drugs and strategies around ASCT for Hodgkin lymphoma

Presented By
Dr Anna Sureda, Catalan Institute of Oncology, Spain
Conference
EBMT 2023
Type
Peer-reviewed article

15 June 2023 17:15

Abscopal response in patients with relapsed or refractory Hodgkin lymphoma who failed on anti-PD1 treatment

Presented By
Dr Paul Bröckelmann, University Hospital of Cologne, Germany
Trial
Phase 2, AERN
Conference
EHA 2022
Type
News article

1 July 2022 11:37

Psoriasis associated with a higher cancer risk

Presented By
Mr Alex Trafford, University of Manchester, UK
Conference
PFGC 2021
Type
Peer-reviewed article

2 February 2022 14:23

Low numbers of M2 macrophages in tumour microenvironment associated with superior response to immunotherapy in Hodgkin lymphoma

Presented By
Dr Liudmila Fedorova, Pavlov University, Russia
Conference
ESMO 2021
Type
Peer-reviewed article

19 November 2021 09:18

Immuno-oncology agents are effective in treating classic Hodgkin’s lymphoma

Presented By
Dr Marc André, Centre Hospitalier Universitaire UCL Namur, Belgium
Trial
CheckMate 205; KEYNOTE-087
Conference
EHA 2021
Type
Peer-reviewed article

5 August 2021 12:26

PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma

Presented By
Dr Peter Borchmann, University Hospital of Cologne, Germany
Trial
Phase 3, HD17
Conference
EHA 2020
Type
Peer-reviewed article

9 September 2020 12:51

Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma

Presented By
Prof. Pier Luigi Zinzani, University of Bologna, Italy
Trial
Phase 3, KEYNOTE-204
Conference
EHA 2020
Type
Peer-reviewed article

9 September 2020 12:38

Nivolumab/brentuximab vedotin in R/R HL: good CMR rates

Presented By
Prof. Christine Mauz-Körholz, Justus-Liebig-Universität Gießen, Germany
Trial
Phase 2, Checkmate 744
Conference
EHA 2020
Type
Peer-reviewed article

28 August 2020 12:09

Brentuximab vedotin continues to demonstrate superior clinical activity in classical Hodgkin lymphoma

Presented By
Dr Steven Horwitz , Memorial Sloan Kettering Cancer Center, USA
Trial
Phase 3, ECHELON-1
Conference
EHA 2019
Type
Peer-reviewed article

9 August 2019 20:49
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com